Which medications in the drug class Selective Inhibitor of Nuclear Export are used in the treatment of Multiple Myeloma?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Selective Inhibitor of Nuclear Export

The first selective inhibitor of nuclear export (SINE) was approved by the FDA in July 2019. These agents act on tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1). Inhibition of XPO1 leads to accumulation of TSPs in the nucleus, reductions in several oncoproteins (eg, c‐myc, cyclin D1), cell cycle arrest, and apoptosis of cancer cells.

Selinexor (Xpovio)

Indicated in combination with dexamethasone for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!